» Articles » PMID: 38555425

Novel Insights and New Therapeutic Potentials for Macrophages in Pulmonary Hypertension

Overview
Journal Respir Res
Specialty Pulmonary Medicine
Date 2024 Mar 30
PMID 38555425
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammation and immune processes underlie pulmonary hypertension progression. Two main different activated phenotypes of macrophages, classically activated M1 macrophages and alternatively activated M2 macrophages, are both involved in inflammatory processes related to pulmonary hypertension. Recent advances suggest that macrophages coordinate interactions among different proinflammatory and anti-inflammatory mediators, and other cellular components such as smooth muscle cells and fibroblasts. In this review, we summarize the current literature on the role of macrophages in the pathogenesis of pulmonary hypertension, including the origin of pulmonary macrophages and their response to triggers of pulmonary hypertension. We then discuss the interactions among macrophages, cytokines, and vascular adventitial fibroblasts in pulmonary hypertension, as well as the potential therapeutic benefits of macrophages in this disease. Identifying the critical role of macrophages in pulmonary hypertension will contribute to a comprehensive understanding of this pathophysiological abnormality, and may provide new perspectives for pulmonary hypertension management.

Citing Articles

GPS2 ameliorates cigarette smoking-induced pulmonary vascular remodeling by modulating the ras-Raf-ERK axis.

Hu T, Mu C, Li Y, Hao W, Yu X, Wang Y Respir Res. 2024; 25(1):210.

PMID: 38755610 PMC: 11100185. DOI: 10.1186/s12931-024-02831-0.

References
1.
Kumar R, Mickael C, Kassa B, Sanders L, Hernandez-Saavedra D, Koyanagi D . Interstitial macrophage-derived thrombospondin-1 contributes to hypoxia-induced pulmonary hypertension. Cardiovasc Res. 2019; 116(12):2021-2030. PMC: 7519884. DOI: 10.1093/cvr/cvz304. View

2.
Dignam J, Sharma S, Stasinopoulos I, MacLean M . Pulmonary arterial hypertension: Sex matters. Br J Pharmacol. 2023; 181(7):938-966. DOI: 10.1111/bph.16277. View

3.
Gao R, Wang M, Liu Q, Feng D, Wen Y, Xia Y . Hypoxia-Inducible Factor-2α Reprograms Liver Macrophages to Protect Against Acute Liver Injury Through the Production of Interleukin-6. Hepatology. 2019; 71(6):2105-2117. PMC: 7075728. DOI: 10.1002/hep.30954. View

4.
Hu L, Yu Y, Shen Y, Huang H, Lin D, Wang K . Ythdf2 promotes pulmonary hypertension by suppressing Hmox1-dependent anti-inflammatory and antioxidant function in alveolar macrophages. Redox Biol. 2023; 61:102638. PMC: 9975317. DOI: 10.1016/j.redox.2023.102638. View

5.
Calvier L, Herz J, Hansmann G . Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmonary Hypertension. JACC Basic Transl Sci. 2022; 7(2):164-180. PMC: 8897182. DOI: 10.1016/j.jacbts.2021.09.011. View